Friday, February 25, 2011 11:23:38 PM
Recent CHRS News
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting • GlobeNewswire Inc. • 04/08/2024 12:30:00 PM
- Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update • GlobeNewswire Inc. • 03/13/2024 08:01:00 PM
- Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 • GlobeNewswire Inc. • 03/05/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 11:22:53 AM
- Coherus Completes Divestiture of Ophthalmology Franchise • GlobeNewswire Inc. • 03/04/2024 06:00:00 AM
- Coherus BioSciences Announces New Employment Inducement Grants • GlobeNewswire Inc. • 02/23/2024 10:33:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:02:44 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:59:29 PM
- Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv • GlobeNewswire Inc. • 02/21/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:09:45 PM
- Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP • GlobeNewswire Inc. • 02/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 01:05:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 01:04:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:01:00 PM
- Sandoz to Acquire Cimerli Business from Coherus for $170 Million • Dow Jones News • 01/22/2024 06:59:00 AM
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal • GlobeNewswire Inc. • 01/22/2024 06:15:00 AM
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium • GlobeNewswire Inc. • 01/18/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 02:41:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 02:39:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 12:37:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 11:58:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:14:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:13:16 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
FEATURED Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • Apr 16, 2024 8:52 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM
Avant Technologies Begins Development on Next-Generation AI-Driven Resource Allocation Solution • AVAI • Apr 16, 2024 8:00 AM
UC Asset Expected to Report $0.03/share Net Profit for 2023 • UCASU • Apr 11, 2024 10:00 AM